Table of Contents

July 1, 2014 • Volume 20 • Number 13

Highlights of This Issue 3359

SPECIAL FEATURES

CCR Translations

3361  MET as a Target in Papillary Renal Cell Carcinoma
André P. Fay, Sabina Signoretti, and Toni K. Choueiri
See related article, p. 3411

CCR Perspectives in Drug Approval

3364  U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

Statistics in Clinical Cancer Research

3371  Blocking and Randomization to Improve Molecular Biomarker Discovery
Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafañia, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

Molecular Pathways

3379  Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
Mark A. Dickson

3384  Molecular Pathways: Niches in Metastatic Dormancy
Konji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

Review

3390  Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
Wing Leung

HUMAN CANCER BIOLOGY

3401  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
Yong-Chen Lu, Xin Yao, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

3411  MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of PRCC with CGH Array and Matching Gene Expression Array
Laurence Albiges, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camparo, Zahâra Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couden, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier
See related article, p. 3361

3422  Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer
Natalie Hartmann, Nathalia A. Giese, Thomas Giese, Isabel Poschke, Rienk Offringa, Jens Werner, and Eduard Ryschich

3434  Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer
Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

CANCER THERAPY: PRECLINICAL

3446  Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglia, Björn Titz, Thinle Chodon, Thomas G. Graeber, Begonya Comin-Anduix, and Antoni Ribas
Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamatsu, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhito Takenoyama, Tokujiro Yano, and Yoshihiko Maehara

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihuaxiong, and Xianglin Yuan

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.